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and are exposed to
CSF-1 in vivo.
• Inhibition of CSF-1R
signaling reduces via-
bility of inv(16) AML
cells in vitro and in
therapeutic settings in
humanized mice in vivo.
Introduction
Inversion of chromosome 16 [inv(16)(p13q22)], resulting in the fusion transcript CBFb-MYH11,
is a chromosomal rearrangement recurrently found in acute myeloid leukemia (AML).1,2 Although
AML with inv(16) has a comparatively favorable outcome upon standard chemotherapy, almost
half of patients eventually relapse. Thus, a better understanding of disease pathophysiology and
improved treatments are necessary.3 We recently demonstrated that human inv(16) AML cells
express colony-stimulating factor 1 receptor (CSF-1R) and that human colony-stimulating factor
1 (CSF-1) was required for high-level in vivo engraftment of inv(16) AML cells in immunodeficient
mice.4,5 Here, we consequently tested whether CSF-1 can be measured in inv(16) AML patient
sera and if inhibition of CSF-1R signaling can selectively inhibit inv(16) AML growth in vitro
and in vivo.
Methods
AML cells were obtained upon written informed consent from patients with newly diagnosed AML
(Cantonal Ethics Committee of Zurich; KEK-ZH-Nr. 2009-0062/1). AML karyotypes and mutational
status are provided in supplemental Table 1. Mononuclear cells (MNCs) were purified by density
gradient centrifugation. CD3- and CD19-expressing cells were depleted by immunomagnetic
separation. AML cells were cultured in Iscove modified Dulbecco medium supplemented with 20%
fetal bovine serum, 1% bovine serum albumin, 2 mM L-glutamine, 50 mM 2-mercaptoethanol, antibiotics,
human interleukin-3 (IL-3; 20 ng/mL), IL-6 (10 ng/mL), IL-11 (10 ng/mL), granulocyte-macrophage
colony-stimulating factor (50 ng/mL), stem cell factor (10 ng/mL), Flt3 ligand (10 ng/mL), and
thrombopoietin (50 ng/mL)6CSF-1 (20 ng/mL). Humanized cytokine knockin mice (MISTRG) were
generated as reported previously.6 Newborn mice were sublethally irradiated with 1 3 150 cGy.
A total of 1 3 106 primary AML cells (in 20 mL phosphate-buffered saline) were injected
intrahepatically using a 30-G needle.4,7 Mice were treated and analyzed as indicated in supplemental
Methods.
Results and discussion
To determine if CSF-1 is measurable in inv(16) AML patients and thus CSF-1R on inv(16) AML cells
might be stimulated via this pathway, we analyzed CSF-1 levels in plasma from inv(16) AML patients
(n5 13), non-inv(16) AML patients (n5 37), and patients without a hematological disease (n5 15).
CSF-1 levels varied widely, with a mean concentration of 400 pg/mL in the inv(16) AML cohort, 139
pg/mL in the non-inv(16) AML cohort, and 130 pg/mL in patients without a hematological disease
(Figure 1A), although these differences were not statistically significant. In line with prior results, we
detected a relative upregulation of CSF-1R in bone marrow cells of inv(16) AML, but not in other
genetically defined AML types, using microarray data from an international cohort study (n 5 536)
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(supplemental Figure 1A; supplemental Table 2).8 Interestingly,
while strong CSF-1R upregulation was unique to inv(16)
AML, the data also demonstrate overexpression of other cy-
tokine receptors in different genetically defined AML sub-
groups, indicating their possible biological roles in those
AML entities.9
To test whether CSF-1 is of relevance for inv(16) AML cell survival
in vitro, we cultured primary human inv(16) AML cells with a mixture
of hematopoietic progenitor cell supporting cytokines at saturating
doses, with or without the addition of CSF-1. While AML cells
showed a certain degree of maturation, immature surface markers
were maintained during the 10-day culture period (supplemental
Figure 1B). Importantly, inv(16) AML cells incubated without CSF-1
showed a significantly lower viability when compared with those
incubated with CSF-1, and positive effects of CSF-1 were abrogated
by MCS110, a monoclonal CSF-1 neutralizing antibody (Figure 1B).
In stark contrast, we observed no impact on in vitro survival of non-
inv(16) AML samples by the addition of CSF-1 and its neutralization
via MCS110 (Figure 1C).
We then evaluated inhibition of CSF-1R signaling via the selective
tyrosine kinase inhibitor BLZ945. As expected, inhibition of CSF-1R
resulted in reduced phosphorylation of downstream targets p44/42
MAPK (ERK-1/2) and Akt (Figure 1D).10 In line with these findings
and supporting the importance of this signaling pathway in inv(16)
AML, transcriptomic analysis showed an enhanced positive regu-
lation of the MAPK/ERK pathway in inv(16) AML compared with
other AML subtypes (supplemental Figure 1C). Incubation of










































































































































































































inv(16) AMLA B C
Figure 1. CSF-1R signaling promotes and signaling-inhibition decreases survival of inv(16) AML cells in vitro. (A) Plasma from peripheral blood was
collected from inv(16) AML patients (n 5 14), non-inv(16) AML patients (n 5 37), and patients without a hematological disease (n 5 15). AML samples were
collected at first diagnosis or relapse, and CSF-1 concentration in blood was measured by enzyme-linked immunosorbent assay. Graph shows mean 6 standard error
of the mean. (B) Analysis of viability of different primary inv(16) AML (n 5 5) (B) and non-inv(16) AML (n 5 6) (C) samples (CD3/CD19 depleted) after incubation for
10 days with or without CSF-1 and MCS110 (40 mg/mL), a monoclonal blocking anti-CSF-1 antibody, respectively. Viability was determined by flow cytometry. (D)
Western blot analysis of CSF-1R downstream signaling pathways, including phospho-p44/42 MAPK (Thr202/Tyr204) and phospho-Akt (Ser473), in primary AML with
inv(16) cells in response to CSF-1 and the CSF-1R inhibitor BLZ945. Before incubation with CSF-1 (30 minutes) and BLZ945 (200 mg/mL) (2 hours), cells were
starved in cytokine-free medium for 2 hours. GAPDH and total p44/42 MAPK/Akt are included as loading controls (experiment representative of n 5 3). (E) Primary
inv(16) AML (n 5 5) and non-inv(16) AML (n 5 7) samples (CD3/CD19 depleted) were cultured for 10 days in the presence of CSF-1 (20 ng/mL) with different
concentrations of BLZ945 or a vehicle control (Captisol 20%) or left untreated. Viability was analyzed by flow cytometry. Data indicate viability of primary AML cells relatively to
untreated cells (control). (F) Metabolic activity of primary inv(16) AML (n 5 6) and non-inv(16) AML (n 5 6) in response to different concentrations of BLZ945 determined by
MTT assay at day 3. Changes are calculated relative to untreated cells. (G) CSF-1R expression analysis by quantitative polymerase chain reaction of non-inv(16) (n 5 6) and
inv(16) (n 5 6) AML samples. Graph indicates the log2 of the ratio of the Ct values of CSF1R to the reference gene GAPDH for each sample. Graphs show mean 6 standard
error of the mean. *P , .05; **P , .01; ***P , .001. ns, not significant.














































































































































































































































































































































Figure 2. CSF-1R inhibition reduces inv(16) AML growth in a therapeutic xenograft model. (A) Plasma from adult MISTRG (n 5 8) was collected, and CSF-1
concentration was measured by enzyme-linked immunosorbent assay. (B) Experimental scheme: 1 3 106 primary AML cells (inv(16), n 5 4 different patients; non-inv(16),
n 5 3) were transplanted intrahepatically into irradiated newborn mice (MISTRG). Upon detection of human blasts in peripheral blood, the CSF-1R inhibitor BLZ945
(200 mg/kg) or a vehicle (equivalent amount Captisol 20%) was orally administered daily for 21 days. AML engraftment was determined in blood prior to treatment and in
blood, bone marrow, and spleen after treatment. (C) AML engraftment (human CD451 cells of total CD451 cells) of the vehicle control (blue) and BLZ945 (red) cohort prior to
treatment. (D-E) Human inv(16) AML (D) and non-inv(16) AML (E) engraftment (human CD451 cells of total CD451 cells) of the vehicle control (blue) and BLZ945 (red)
cohort in peripheral blood (left) (day 0 [d0], start of treatment), bone marrow (middle), and spleen (right) after 21 days (d21) of application (inv(16) AML, n 5 24; non-inv(16),
n 5 9). (F) Demonstration of myeloblasts and multiple intracellular Auer rods (black arrow) in a myeloid leukemic blast in the bone marrow of a MISTRG mouse engrafted with
human AML with inv(16) cells (Giemsa stain). (G) Representative images of bone marrow histology of inv(16) AML engrafted MISTRG mice, detecting human CD45 and
CD34. Small letters in panel C (vehicle 5 a; BLZ945 5 b) point out engraftment levels measured by flow cytometry in the bone marrow of the animals shown. Graphs show
mean (black bar) 6 standard error of the mean. *P , .05; **P , .01; ***P , .001. H&E, hematoxylin and eosin.
































































































viability and increased apoptotic cell death when compared with
non-inv(16) AML cells (Figure 1E; supplemental Figure 2A-C).
Correspondingly, incubation of inv(16) AML cells with BLZ945
led to a reduced metabolic activity as detected by MTT assay
at day 3 and day 6 compared with non-inv(16) cells (Figure 1F;
supplemental Figure 2D). In contrast, in vitro treatment of non-inv(16)
AML with BLZ945 showed no statistically significant effect on cell
viability compared with untreated cells at low BLZ945 concen-
trations, but only at doses$100mg/mL (supplemental Figure 2E-G).
BLZ945 at higher doses might inhibit other relevant tyrosine
kinases, notwithstanding its relatively high target specificity,
a hypothesis supported by the finding that non-inv(16) AML was
neither stimulated by CSF-1 nor inhibited by CSF-1 neutraliza-
tion (Figure 1C). Also, higher concentrations of BLZ945 showed
cytotoxic effects on healthy human bone marrow cells, poten-
tially indicating on- and off-target reactivity of this substance
(supplemental Figure 2H). To further reveal mechanisms of
CSF-1 dependence and possibly predict the response to CSF-1R
inhibition, we analyzed CSF-1R expression levels in primary AML
cells by quantitative polymerase chain reaction. As expected,
inv(16) AML cells showed increased expression levels compared
with non-inv(16) (Figure 1G). A subanalysis revealed a correla-
tion of CSF-1R expression levels and in vitro response rates to
BLZ945 (supplemental Figure 2I). Moreover, we analyzed CSF-1
serum levels of patients at diagnosis and response rates to
BLZ945. Here, we could observe the tendency that primary
AML cells from patients with high CSF-1 serum levels showed
increased cytotoxicity in response to BLZ945 treatment in vitro
(supplemental Figure 2J).
To test the effectiveness of BLZ945 on inv(16) AML growth
inhibition in vivo, we established a therapeutic xenograft model
using Rag2-, Il2rg-deficient mice, in which mouse cytokines
(macrophage colony-stimulating factor/CSF-1, IL-3, granulocyte-
macrophage colony-stimulating factor, and thrombopoietin) were
replaced by their human counterparts at the respective mouse loci.6
Of note, these mice have similar human CSF-1 plasma levels as
human inv(16) AML patients (average concentration of 767 pg/mL)
(Figures 1A and 2A). Mice were transplanted with patient-derived
inv(16) AML or non-inv(16) AML cells. Upon detection of AML
blasts in peripheral blood, mice were allocated to 2 groups,
matched by leukemia engraftment levels. Animals were sub-
sequently treated daily with BLZ945 (200 mg/kg) or control
Captisol 20% (vehicle) orally for 21 days (Figure 2B-C). BLZ945
was well tolerated, with no weight loss and without impaired mouse
hematopoiesis in both MISTRG and wild-type mice (supplemental
Figures 3A-G and 4A-E). Human AML engraftment in mice was
analyzed upon termination by flow cytometry and defined as
percentage of human CD451 of all CD451 cells (human and mice)
(Figure 2C, supplemental Figure 4F). BLZ945 treatment resulted in
significantly reduced growth of inv(16) AML in bone marrow, blood,
and spleen compared with the vehicle control group (Figure 2D;
supplemental Table 3). By testing a small cohort of mice transplanted
with non-inv(16) AML primary cells, our data indicate a lower
sensitivity of non-inv(16) AML cells to BLZ945 in vivo (Figure 2E).
The data obtained by flow cytometry were also verified by cytology
(Figure 2F) and bone marrow histology analysis (Figure 2G).
However, further studies are required to clarify the susceptibility of
different AML subtypes to CSF-1R inhibitors as a single agent or in
combination therapies.
In summary, we demonstrate significantly reduced viability of inv(16)
AML cells in vitro and in vivo in response to CSF-1R signaling
inhibition. Importantly, xenograft studies in humanized MISTRG mice
closely reflect exposition of AML to CSF-1 in patients, thus
suggesting that the inhibitory effect of BLZ945 could indeed also
apply in a clinical setting. However, while inv(16) AML growth
was significantly reduced by CSF-1R signaling inhibition, a
relevant portion of inv(16) AML cells survived treatment dur-
ing the experimental observation time. Thus, not surprisingly,
CSF-1R inhibition is unlikely to be sufficiently effective as single-
agent therapy. It is important to point out in this context that
midostaurin, the first US Food and Drug Administration–approved
inhibitor of the recurrently mutated and constitutively activated
membrane tyrosine kinase FLT3, also primarily showed a growth
deceleration rather than an eradication of AML cells in a xenograft
model.11
Concurrently with our data, a recent study showed that CSF-1R
inhibition reduces in vitro cell viability in .20% of AML patient
samples due to inactivation of paracrine signals by support-
ive cells.12 Interestingly, the CSF-1R inhibitor (GW2580) used
in this study was found to inhibit preferentially de novo and
favorable-risk (European LeukemiaNet classification) AML patient
samples.
Independently of AML, the use of CSF-1R inhibitors demon-
strated a favorable safety profile in patients with solid tumors.13
Currently, 2 clinical trials are recruiting to test the safety,
tolerability, and efficacy of BLZ945 in nonhematological dis-
eases (NCT02829723 and NCT04066244). The first results
revealed a tolerable safety pattern without severe hematotoxic
side effects.14
However, CSF-1R inhibition in cancer has to be evaluated carefully,
as unexpected effects may occur. In a murine model of spontaneous
metastasis from primary Lewis lung carcinoma tumors in immunocom-
petent mice, inhibition of CSF-1R increased the risk of developing
metastatic disease by reducing the number of natural killer cells due to
a lack of myeloid cells that provide IL-15.15 Interestingly, administration
of exogenous IL-15 during treatment restores natural killer cell numbers
and metastasis control.
In summary, CSF-1R inhibition might be a promising target in AML
treatment of specific subgroups like AML with inv(16) and should be
evaluated in further studies.
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